Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125285231 | 12528523 | 1 | I | 20160628 | 20160705 | 20160705 | EXP | CA-PFIZER INC-2016327162 | PFIZER | POPADIUK, C.. PEGYLATED LIPOSOMAL DOXORUBICIN IS AN ACTIVE AGENT FOR CHEMOTHERAPY-RESISTANT CHORIOCARCINOMA: A REPORT OF TWO CASES. JOURNAL OF REPRODUCTIVE MEDICINE. 2016;61 (5-6):215-218 | 33.00 | YR | F | Y | 0.00000 | 20160705 | MD | CA | CA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125285231 | 12528523 | 1 | SS | ETOPOSIDE. | ETOPOSIDE | 1 | UNK UNK, CYCLIC | 0 | |||||||||||
| 125285231 | 12528523 | 2 | PS | METHOTREXATE SODIUM. | METHOTREXATE SODIUM | 1 | UNK UNK, CYCLIC | 11719 | |||||||||||
| 125285231 | 12528523 | 3 | SS | VINCRISTINE SULFATE. | VINCRISTINE SULFATE | 1 | UNK UNK, CYCLIC | 71484 | |||||||||||
| 125285231 | 12528523 | 4 | SS | CISPLATIN. | CISPLATIN | 1 | U | 0 | |||||||||||
| 125285231 | 12528523 | 5 | SS | GEMCITABINE HYDROCHLORIDE. | GEMCITABINE HYDROCHLORIDE | 1 | UNK | U | 78339 | POWDER FOR INJECTION | |||||||||
| 125285231 | 12528523 | 6 | SS | ACTINOMYCIN D | DACTINOMYCIN | 1 | UNK | 0 | |||||||||||
| 125285231 | 12528523 | 7 | SS | CYCLOPHOSPHAMIDE. | CYCLOPHOSPHAMIDE | 1 | UNK | 0 | |||||||||||
| 125285231 | 12528523 | 8 | SS | TAXOL | PACLITAXEL | 1 | UNK | U | 0 | ||||||||||
| 125285231 | 12528523 | 9 | SS | PEGYLATED LIPOSOMAL DOXORUBICIN HCL | DOXORUBICIN HYDROCHLORIDE | 1 | 35 MG/M2, CYCLIC, EVERY 4 WEEKS | 0 | 35 | MG/M**2 | |||||||||
| 125285231 | 12528523 | 10 | C | DOXORUBICIN | DOXORUBICIN | 1 | 35 MG/M2, EVERY 4 WEEKS | 0 | 35 | MG/M**2 | |||||||||
| 125285231 | 12528523 | 11 | C | TAXOTERE | DOCETAXEL | 1 | UNK | 0 | |||||||||||
| 125285231 | 12528523 | 12 | C | HERCEPTIN | TRASTUZUMAB | 1 | UNK | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125285231 | 12528523 | 1 | Choriocarcinoma |
| 125285231 | 12528523 | 2 | Choriocarcinoma |
| 125285231 | 12528523 | 3 | Choriocarcinoma |
| 125285231 | 12528523 | 4 | Choriocarcinoma |
| 125285231 | 12528523 | 5 | Choriocarcinoma |
| 125285231 | 12528523 | 6 | Choriocarcinoma |
| 125285231 | 12528523 | 7 | Choriocarcinoma |
| 125285231 | 12528523 | 8 | Choriocarcinoma |
| 125285231 | 12528523 | 9 | Choriocarcinoma |
| 125285231 | 12528523 | 10 | Invasive ductal breast carcinoma |
| 125285231 | 12528523 | 11 | Invasive ductal breast carcinoma |
| 125285231 | 12528523 | 12 | Invasive ductal breast carcinoma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125285231 | 12528523 | DE |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125285231 | 12528523 | Acute myeloid leukaemia | |
| 125285231 | 12528523 | Second primary malignancy |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |